{"tid":2430468,"cid":5,"subCid":10,"title":"科興疫苗第三期臨牀數據係咪仍然未獲世衛批准？","createTime":"2021-03-03T03:09:17.000Z","updateTime":"2021-03-03T04:28:15.000Z","uid":79563,"like":3,"dislike":0,"uniUserReply":2,"replies":[{"pid":"4e77f19df438b33edfbb54e46cece33e55479bf6","tid":2430468,"uid":79563,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-03-03T03:09:17.000Z","msg":"【明報專訊】疫苗顧問專家委員會昨開第二次會議，審核中國科興疫苗，結果認為疫苗有效益、安全性高，但要求提交進一步資料，包括相隔14日及28日接種第二劑疫苗有何分別，如接種者產生的抗體水平、副作用等，兩周後再議。科興疫苗的第三期臨牀數據未符合專家委員會的個別指引，即未刊於經同行評審的醫學期刊，亦未獲世衛批准。委員會成員解釋，大部分委員會成員都為期刊評審，會以相同尺度審視科興數據，且科興已在多國獲批緊急使用，可靈活處理。<br />\n<br />\n<a href=\"https://health.mingpao.com/新冠疫苗-科興疫苗巴西第三期臨牀研究-60歲以上長/\" data-sr-url=\"https://r.lihkg.com/link?u=https%3A%2F%2Fhealth.mingpao.com%2F%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97-%E7%A7%91%E8%88%88%E7%96%AB%E8%8B%97%E5%B7%B4%E8%A5%BF%E7%AC%AC%E4%B8%89%E6%9C%9F%E8%87%A8%E7%89%80%E7%A0%94%E7%A9%B6-60%E6%AD%B2%E4%BB%A5%E4%B8%8A%E9%95%B7%2F&d=uMWHtpimsJ%2FyHBgDjrBiuk5YX6KrfwXAFWAh9WWXcag%3D&h=f939e3e2\" data-ef-url=\"https://embed.lih.kg/frame?u=https%3A%2F%2Fhealth.mingpao.com%2F%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97-%E7%A7%91%E8%88%88%E7%96%AB%E8%8B%97%E5%B7%B4%E8%A5%BF%E7%AC%AC%E4%B8%89%E6%9C%9F%E8%87%A8%E7%89%80%E7%A0%94%E7%A9%B6-60%E6%AD%B2%E4%BB%A5%E4%B8%8A%E9%95%B7%2F&h=d65d3ec2\" target=\"_blank\">https://health.mingpao.com/新冠疫苗-科興疫苗巴西第三期臨牀研究-60歲以上長/</a>"},{"pid":"ee9a414e26341d91bdd876a9bd802be7232144fe","tid":2430468,"uid":26329,"like":1,"dislike":0,"score":1,"citedBy":1,"replyTime":"2021-03-03T04:11:08.000Z","msg":"等緊香港既數據<img src=\"/assets/faces/normal/smile.gif\" class=\"hkgmoji\" />"},{"pid":"6c722ef04cbe71d619d3741e8f5549e7d375f586","tid":2430468,"uid":79563,"like":1,"dislike":0,"score":1,"quote":{"pid":"ee9a414e26341d91bdd876a9bd802be7232144fe","tid":2430468,"uid":26329,"like":1,"dislike":0,"score":1,"citedBy":1,"replyTime":"2021-03-03T04:11:08.000Z","msg":"等緊香港既數據<img src=\"/assets/faces/normal/smile.gif\" class=\"hkgmoji\" />"},"citedBy":0,"replyTime":"2021-03-03T04:28:15.000Z","msg":"等埋香港數據, 先上到期刊？"}]}